IP Library Granted Patent US 7,101,980
Granted Patent B2
US 7,101,980 · App. 10/622,524 · Granted Sep 5, 2006

Derivatives, conjugates, and antibodies for detecting ecstasy-class analytes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,101,980
App. No.
10/622,524
Granted
Sep 5, 2006
Kind
B2
Abstract

Compounds including haptens, intermediates, and immunogens that are useful in the production of antibodies specific for the methylenedioxy class of amphetamine derivatives are described. Antibodies specific for the methylenedioxy class of amphetamine derivatives, reagent kits containing antibodies specific for the methylenedioxy class of amphetamine derivatives, methods of producing antibodies specific for the methylenedioxy class of amphetamine derivatives, and methods of detecting analytes including members of the methylenedioxy class of amphetamine derivatives are also described.

Claims (31)

1. A compound having the structure

wherein

R 1 is an alkyl group comprising 2–6 carbon atoms,

R 2 is selected from the group consisting of hydrogen and protectng groups,

R 3 is an optionally substituted alkyl group comprising 1–4 carbon atoms, and

Z is L-X-Q wherein L is (CH 2 ) 3 , X is CO, and Q is selected from the group consisting of macromolecular carriers and labels.

2. The compound of claim 1 wherein the macromolecular carrier is selected from the group consisting of proteins, polypeptides, and polysaccharides.

3. The compound of claim 1 wherein the macromolecular carrier is selected from the group consisting of keyhole limpet hemocyanin, bovine serum albtumin, and bovine thyroglobulin.

4. Cell line NEAMP 48.2, ATCC designation PTA-2595, producing a monoclonal antibody binding preferentially to MDEA.

5. A monocional antibody produced from cell line NEAMP 48.2, ATCC designation PTA-5295, the antibody binding preferentially to MDEA.

6. Cell line NEAMP 62. , ATCC designation PTA-5294, producing a monoclonal antibody binding preferentially to MDEA.

7. A monoclonal antibody prodoced from cell line NEAMP 62.1, ATCC designation PTA-5294, the antibody binding preferentially to MDEA.

8. An antibody generated in response to a compound having the structure

wherein

R 1 is an alkyl group comprising 2–6 carbon atoms,

R 2 is selected from the group consisting of hydrogen and protecting groups,

R 3 is an optionally substituted alkyl group comprising 1–4 carbon atoms, and

Z is L-X-Q wherein L is (CH 2 ) 3 , X is CO, and Q is a macromolecular carrier selected from the group consisting of proteins, polypeptides, and polysaccharides.

9. The antibody of claim 8 wherein the protein is selected fron the group consisting of keyhole limpet hemocyanin, bovine serum albumin, and bovine thyroglobulin.

10. The antibody of claim 8 wherein R 3 is ethyl and R 3 is methyl.

11. A method for producing an antibody comprising inoculating a host with an immunogen having the structure

wherein

R 1 is an alkyl group comprising 2–6 carbon atoms,

R 2 is selected from the group consisting of hydrogen and protecting groups,

R 3 is an optionally substituted alkyl group comprising 1–4 carbon atoms, and

Z is L-X-Q wherein L is (CH 2 ) 3 , X is CO, and Q is a macromolecular carrier selected from the group consisting of proteins, polypeptides, and polysaccharides.

12. The method of claim 11 wherein R 1 is ethyl and R 3 is methyl.

13. The method of claim 11 wherein Q is a protein selected from the group consisting of hemocyanins, globulins, and albumins.

14. A method for detecting an analyte in a sample, the analyte comprising an ecstasy drug or an ecstasy drug derivative, comprising:

contacting the sample with the antbody of claim 8 and a conjugate comprising an analyte analog and a detectable label whereby the analyte and the analog compete for binding to the a antibody, and

measureing the labeled conjugate bound to the antibody or measuring the unbound labeled conjugate as a a measure of the analyte in the sample.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2004
From: ROCHE DIAGNOSTICS CORPORATION
To: ROCHE DIAGNOSTICS OPERATIONS, INC.
Reel/Frame 015201/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2003
From: HUI, RAYMOND A.; VITONE, STEPHEN; ROOT, RICHARD TERRY; BABURINA, IRINA; JORDAN, SHERI
To: ROCHE DIAGNOSTICS CORPORATION
Reel/Frame 014777/0500 →